📣¿Ya te registraste?
No dejes pasar esta sesión académica donde hablaremos sobre Tratamiento en 1ª línea del cáncer de colon metastásico con inestabilidad microsatelital.
🔗https://t.co/OhfSQztX5P
🗓️Jueves, 24 de julio de 2025
🕗20:00 hrs
#OncologíaMX#SMeO#CáncerColon#Salud
October is Liver Cancer Awareness Month! Let’s join together to raise awareness for cholangiocarcinoma, the second most common liver cancer worldwide. Awareness is the first step toward prevention and finding a cure.
Learn more about #cholangiocarcinoma and how you can help at https://t.co/EkuuLnj2xp.
Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer:
#ESMO24
🔎3-year disease-free survival from NICHE-2
👉💯% DFS
👉all MRD pts cleared ctDNA
🧐Impressive results, ctDNA may be helpful to select for organ preservation
@myESMO#ESMOAmbassadors
Retifanlimab + carboplatin-paclitaxel in 1L squamous cell carcinoma of the anal canal
#ESMO24
🔎POD1UM-303/InterAACT 2
👉mPFS 7.4 vs 9.4 mo
👉mOS 23 vs 29 mo
👉Limited impact of n cross over (45%)
🧐Practice-changing trial
👏excellent discussion by D. Modest
@myESMO #ESMOAmbassadors
⚡️Lower GI- Proffered paper (Day-3) #ESMO24@myESMO
➡️ LEANOX trial
➡️Lean body mass based dosage of oxaliplatin in adjuvant of CRC
✅ peripheral neurotoxicity ⬇️
✅No effect on RFS and OS
@OncoAlert#medx#cancer#oncology
🚨🚨POD1UM-303/InterAACT 2🚨🚨
Inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal
🔎Randomized:
Carbo/Taxol
vs.
Carbo/Taxol + retifanlimab
Addition of retifanlimab associated with:
✅⬆️ OS 29 vs 23 m
✅⬆️ PFS 9 vs 7 m
🔥New SOC!!🔥
#ESMO24